Clinical trials: RAS Wild Type
Neoadjuvant Treatment, Rectal Cancer
Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy
Prospectively Investigate the effectiveness and safety of neoadjuvant cetuximab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS wild-type locally advanced rectal cancer
- Conditions
- Neoadjuvant Treatment, Rectal Cancer, Cetuximab, Radiotherapy
- Trial name
- NCT04923620
- Testing
- cetuximab+mFOLFOX6, short-course radiotherapy
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Shanghai Minimally Invasive Surgery Center
Left-sided Colorectal Cancer
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer located on the left side of the colon that cannot be safely removed by surgery or has spread to other…
- Trial name
- NCT07702032
- Testing
- Petosemtamab, Cetuximab, FOLFIRI
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 960 people
- Sponsor
- Genmab
Colorectal Adenocarcinoma Metastatic to the Liver
Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver
The purpose of this study is to see if patients treated with both regional chemotherapy using the HAI pump and intravenous chemotherapy are able to have their liver tumors removed surgically (resected), versus treatment with only…
- Trial name
- NCT03069950
- Testing
- Floxuridine (FUDR), Irinotecan (CPT-11), FLUOROURACIL
- Where
- 5 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Refractory Metastatic Colorectal Cancer
Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
This study is designed as an international, open-label, controlled two-arm, randomized phase III comparison study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus…
- Trial name
- SUNLIGHT (NCT04737187)
- Testing
- Trifluridine/Tipiracil, Bevacizumab
- Where
- 99 sites in United States, Austria and 12 more
- Volunteers
- 492 people
- Sponsor
- Taiho Oncology, Inc.
Colorectal Neoplasms, Chemotherapy Effect
Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer
Patients meeting the inclusion criteria will be randomized 1:1 into Cohort A (n ≈ 177) or Cohort BC (n ≈ 177). Cohort A is the control: patients receive combination chemotherapy with FOLFOX plus anti-EGFR therapy (panitumumab or…
- Conditions
- Colorectal Neoplasms, Chemotherapy Effect, Molecular Sequence Variation
- Trial name
- CRC01 (NCT06226857)
- Testing
- Cetuximab
- Where
- 3 sites in Russia
- Volunteers
- 355 people
- Sponsor
- City Clinical Oncology Hospital No 1
Colorectal Cancer
Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer
RATIONALE: Brivanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00640471
- Testing
- cetuximab, brivanib alaninate
- Where
- 37 sites in Canada
- Volunteers
- 750 people
- Sponsor
- NCIC Clinical Trials Group
Metastatic Colorectal Cancer
EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer
The purpose of this study is to assess the safety and clinical activity of the experimental drug EMD 525797 (study drug), a monoclonal antibody targeting alfa integrins, in combination with irinotecan and cetuximab in K-ras…
- Trial name
- POSEIDON (NCT01008475)
- Testing
- EMD 525797 250 mg, EMD 525797 500 mg, EMD 525797 750 mg
- Where
- 62 sites in Belgium, Bulgaria and 10 more
- Volunteers
- 232 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Metastatic Colon Cancer
REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients
This is a clinical prospective, no-Profit, Interventional, Premarket Medical Device "early phase", multicentre, single-arm study, based on collecting data on predictive biomarkers of mCRC patients, integrate them with the results…
- Trial name
- REVERT (NCT05396807)
- Testing
- AI
- Where
- 6 sites in Italy, Romania and 1 more
- Volunteers
- 106 people
- Sponsor
- University of Rome Tor Vergata
Metastatic Colorectal Cancer
FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation
Single-arm, multi-centre phase II study The primary objective is to evaluate the time to failure of the strategy.
- Trial name
- OPTIPRIME (NCT03584711)
- Testing
- FOLFOX + panitumumab
- Where
- 124 sites in France, Martinique
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Federation Francophone de Cancerologie Digestive
Colorectal Neoplasms, Colorectal Carcinoma
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
To estimate progression-free survival at one year in elderly patients with RAS/BRAF wild-type unresectable mCRC and good performance status treated with FOLFIRI + panitumumab as first-line therapy.
- Conditions
- Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Cancer Metastatic, Neoplasm Metastasis
- Trial name
- OPALO (NCT03142516)
- Testing
- Panitumumab, Irinotecan, Folinic acid
- Where
- 12 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
RAS Wild-type Metastatic Colorectal Cancer
Pharmacokinetic (PK) Study of QL1203 and Vectibix® for the Treatment of RAS Wild-type Metastatic Colorectal Cancer
This is a randomized, double-blind, parallel-controlled, multicenter clinical trial to evaluate the pharmacokinetic similarity between QL1203 and Vectibix® in patients with RAS wild-type metastatic colorectal cancer.
- Trial name
- NCT07829588
- Testing
- QL1203 + mFOLFOX6, Vectibix®+ mFOLFOX6
- Volunteers
- 136 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Colo-rectal Cancer
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
The purpose of this study is to determine the immunogenicity of the CIMAvaxEGF® vaccine (that is, its effectiveness in inducing an anti-tumor immune response) in patients with metastatic KRAS/NRAS/BRAF wild-type gene colorectal…
- Trial name
- NCT06011772
- Testing
- Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine, Leucovorin, Oxaliplatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Colorectal Cancer
Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC
The aim of the trial is to study the efficacy and safety of Cetuximab re-challenge for Chinese Patients with RAS/BRAF wild-type Metastatic Colorectal Cancer.
- Trial name
- NCT04224415
- Testing
- C225+CPT-11
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Yuhong Li
Colorectal Cancer
Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer
This is an open-label, multicenter, randomized study to be conducted in Chinese patients with RAS and BRAF wild-type mCRC. Patients who have already completed 9 cycles of standard first-line induction treatment, without…
- Trial name
- C-CLASSIC (NCT04262635)
- Testing
- Cetuximab, Capecitabine, Cetuximab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Colon Cancer
Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer
This study was designed as multi-center, ambispective observational trial to evaluate the efficacy and safety of addition of cetuximab to doublet or triplet chemotherapy as conversion therapy in right-sided BRAF/RAS wild-type…
- Trial name
- NCT06322147
- Testing
- Doublet or triplet chemotherapy combined with cetuximab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Qilu Hospital of Shandong University
Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer
This phase I trial studies the side effects and the best dose of irinotecan hydrochloride, based on a genetic test, when given in combination with fluorouracil, leucovorin calcium, and cetuximab as first-line therapy in treating…
- Trial name
- NCT02573220
- Testing
- Cetuximab, Fluorouracil, Irinotecan Hydrochloride
- Where
- Italy
- Sponsor
- University of Chicago
Metastatic Colorectal Cancer
FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)
The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer of RAS wildtype.
- Trial name
- VOLFI (NCT01328171)
- Testing
- FOLFOXIRI + Panitumumab, FOLFOXIRI
- Where
- 19 sites in Germany
- Volunteers
- 93 people
- Sponsor
- AIO-Studien-gGmbH
Treatment Related Cancer
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Within the proposed single arm multicenter phase-II trial it is intended to investigate the feasi-bility of adding Avelumab to FOLFIRI plus Cetuximab after 4 cycles (2 months) of treatment with FOLFIRI plus Cetuximab.
- Trial name
- NCT05217069
- Testing
- 5-FU, Folinic Acid, Irinotecan
- Where
- Germany
- Volunteers
- 57 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Colon Cancer, Organoids
Cetuximab Sensitivity Correlation Between Patient-Derived Organoids and Clinical Response in Colon Cancer Patients.
Eighty patients with RAS/RAF wild-type metastatic right colon cancer will be enrolled and undergo a fresh biopsy of tumor lesion before the standard treatment of chemotherapy.
- Conditions
- Colon Cancer, Organoids, Metastatic Cancer
- Trial name
- NCT04906733
- Testing
- Tumor biopsy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- D1 Medical Technology (Shanghai) Co., Ltd, China
Colon Cancer, Rectal Cancer
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).
- Trial name
- FC-4 (NCT00845039)
- Testing
- Cetuximab, Irinotecan, IMC-A12 (cixutumumab)
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Eli Lilly and Company